{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T16:03:59Z","timestamp":1777565039937,"version":"3.51.4"},"reference-count":30,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T00:00:00Z","timestamp":1626998400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>The bivalent oral poliovirus vaccine (bOPV; Sabin types 1 and 3) replaced the trivalent OPV (Sabin types 1, 2 and 3) globally in April 2016. A routine schedule of 1 dose of inactivated poliovirus vaccine and 3 subsequent doses of bOPV was implemented in Jiangsu simultaneously. The schedule was changed to 2 inactivated poliovirus vaccines +\u20092 bOPV on 1 September 2019. Although OPV type 2 has been removed, challenges persist because of adverse events following immunization (AEFIs) with bOPV. Therefore, we analysed and evaluated the safety profile of bOPV administered in children based on passive postmarketing AEFI surveillance.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We collected all bOPV\u2010related AEFI reports in Jiangsu from the Chinese National AEFI Information System (CNAEFIS) between May 2016 and April 2020. We obtained the administered doses of bOPV from the Jiangsu Provincial Electronic Immunization Registries System. A descriptive analysis was performed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In total, 2084 bOPV\u2010related AEFIs were retrieved from the CNAEFIS. The overall reporting rate was 24.16 per 100\u2009000 doses. Most AEFIs were nonserious. The most frequently reported symptoms were fever, rash and gastrointestinal disorders. Only 1.34% of AEFIs were serious, which thrombocytopenic purpura accounted for the largest category. Seventeen serious adverse events, including 2 vaccine\u2010associated paralytic poliomyelitis (VAPP) cases, were considered to be related to bOPV vaccination. The rate of VAPP was 0.2 per million doses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>AEFI analysis showed that bOPV was well tolerated. The events most frequently reported were nonserious. However, bOPV can still cause VAPP. Attention should be given to risks related to bOPV.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.14976","type":"journal-article","created":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T02:59:30Z","timestamp":1625799570000},"page":"4831-4838","source":"Crossref","is-referenced-by-count":4,"title":["Adverse events following immunization with bivalent oral poliovirus vaccine in Jiangsu, China"],"prefix":"10.1111","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7412-5928","authenticated-orcid":false,"given":"Jun","family":"Gao","sequence":"first","affiliation":[{"name":"Department of Expanded Program on Immunization Jiangsu Provincial Center for Disease Control and Prevention  Nanjing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guodong","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Expanded Program on Immunization Jiangsu Provincial Center for Disease Control and Prevention  Nanjing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ran","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Expanded Program on Immunization Jiangsu Provincial Center for Disease Control and Prevention  Nanjing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Expanded Program on Immunization Jiangsu Provincial Center for Disease Control and Prevention  Nanjing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Expanded Program on Immunization Jiangsu Provincial Center for Disease Control and Prevention  Nanjing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiguo","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Expanded Program on Immunization Jiangsu Provincial Center for Disease Control and Prevention  Nanjing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fenyang","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Expanded Program on Immunization Jiangsu Provincial Center for Disease Control and Prevention  Nanjing China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,7,23]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiw626"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6535a3"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu184"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1586\/erv.12.28"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6530a3"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.11.017"},{"key":"e_1_2_11_8_1","volume-title":"Polio Endgame Strategy 2019\u20132023: Eradication, integration, certification and containment","author":"Global Polio Eradication Initiative","year":"2019"},{"issue":"12","key":"e_1_2_11_9_1","first-page":"CD011260","article-title":"Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis","volume":"12","author":"Ciapponi A","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiw557"},{"key":"e_1_2_11_11_1","unstructured":"World Health Organization.Eradication of polio one step closer for China and the world. Available at:https:\/\/www.unicef.cn\/en\/press-releases\/eradication-polio-one-step-closer-china-and-world. (last accessed 2021 Mar 11)"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit602"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30483-5"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30738-8"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2017.1288769"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.07.042"},{"key":"e_1_2_11_17_1","unstructured":"MillerER SuraghT HibbsB CanoM.Surveillance for Adverse Events Following Immunization Using the Vaccine Adverse Event Reporting System (VAERS). VPD Surveillance Manual. Available at:https:\/\/www.cdc.gov\/vaccines\/pubs\/surv-manual\/chpt21-surv-adverse-events.html(last accessed 2021 July 19)"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.4161\/hv.34360"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2017.1372069"},{"key":"e_1_2_11_20_1","volume-title":"Immunization Safety Surveillance: Guidelines for immunization programme managers on surveillance of adverse events following immunization [S]","author":"World Health Organization Regional Office for the Western Pacific","year":"2016"},{"key":"e_1_2_11_21_1","unstructured":"China Ministry of Health Food and Drug Administration of China.National guideline for the surveillance of adverse events following immunization. Beijing: China Ministry of Health Food and Drug Administration of China;2010. Available at:http:\/\/www.nhc.gov.cn\/jkj\/zcwj2\/new_zcwj_19.shtml(last accessed 2021 Mar 11)"},{"issue":"1","key":"e_1_2_11_22_1","first-page":"9","article-title":"Surveillance of adverse events following immunization in China, 2017","volume":"26","author":"Li K","year":"2020","journal-title":"Chinese J Vaccines Immun"},{"issue":"2","key":"e_1_2_11_23_1","first-page":"139","article-title":"Surveillance of adverse events following immunization for inactivated poliovirus vaccine in China, in 2011\u20102013","volume":"21","author":"Li K","year":"2015","journal-title":"Chinese J Vaccines Immun"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.01.048"},{"key":"e_1_2_11_25_1","volume-title":"The EPI immunization schedule for children and it's instructions (2016 Edition)","author":"China Ministry of Health","year":"2016"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1179\/2047773213Y.0000000113"},{"key":"e_1_2_11_27_1","volume-title":"Supplementary information on vaccine safety; Part 2: Background rates of adverse events following immunization","author":"World Health Organization, Department of Vaccines and Biological","year":"2000"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.107.5.e83"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00219-4"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.01.019"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.epirev.a017991"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.14976","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.14976","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.14976","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T04:55:25Z","timestamp":1693198525000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.14976"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,23]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10.1111\/bcp.14976"],"URL":"https:\/\/doi.org\/10.1111\/bcp.14976","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,23]]}}}